Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019

Hao Zi; Shao-Hua He; Xie-Yuan Leng; Xiao-Feng Xu; Qiao Huang; Hong Weng; Cong Zhu; Lu-Yao Li; Jia-Min Gu; Xu-Hui Li; Dao-Jing Ming; Xiao-Dong Li; Shuai Yuan; Xing-Huan Wang; Da-Lin He; Xian-Tao Zeng

doi:10.1186/s40779-021-00354-z

Your Location：

Home >

Browse articles >

Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019

RESEARCH | Updated：2023-02-28

- Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019
- Military Medical Research Vol. 9, Issue 3, Pages: 303-318(2022)
- Affiliations：
  
  1.Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  2.Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  3.Precision Medicine Centre, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan, China
  4.the First School of Clinical Medicine, Anhui Medical University, Hefei 230000, China
  5.Department of Urology, Xianyang Central Hospital, Xianyang 712000, Hubei, China
  6.Department of Urology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
  7.Institutes of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng 475000, Henan, China
  8.Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China
  9.Institute of Urology, Wuhan University, Wuhan 430071, China
- Author bio：
  
  * yuanshuai021@whu.edu.cn;
  wangxinghuan1965@163.com;
  hedl@xjtu.edu.cn;
  zengxiantao1128@whu.edu.cn; zengxiantao1128@163.com
- Funds：
- DOI：10.1186/s40779-021-00354-z
  CLC：
- Published：2022-06
- Accepted：
Scan QR Code
Zi et al.: Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res, 2021, 8: 60.
DOI：

Zi et al.: Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res, 2021, 8: 60. DOI： 10.1186/s40779-021-00354-z.

摘要

Abstract

Background:

The burden of kidney

bladder

and prostate cancers has changed in recent decades. This study aims to investigate the global and regional burden of

and attributable risk factors for genitourinary cancers during the past 30 years.

Methods:

We extracted data of kidney

bladder

and prostate cancers from the Global Burden of Disease 2019 database

including incidence

mortality

disability-adjusted life-years (DALYs)

and attributable risk factors from 1990 to 2019. Estimated annual percentage changes (EAPC) were calculated to assess the changes in age-standardized incidence rate

age-standardized mortality rate (ASMR)

and age-standardized DALYs rate (ASDR). The associations between cancers burden and socio-demographic index (SDI) were also analyzed.

Results:

Compared with 1990

the global incident cases in 2019 were higher by 154.78%

123.34%

and 169.11% for kidney

bladder

and prostate cancers

respectively. During the 30-year study period

there was a downward trend in ASMR and ASDR for bladder cancer (EAPC=–0.68 and –0.83

respectively) and prostate cancer (EAPC=–0.75 and –0.71

respectively)

but an upward trend for kidney cancer (EAPC=0.35 and 0.12

respectively). Regions and countries with higher SDI had higher incidence

mortality

and DALYs for all three types of cancers. The burden of bladder and prostate cancers was mainly distributed among older men

whereas the burden of kidney cancer increased among middle-aged men. Smoking related mortality and DALYs decreased

but high body mass index (BMI) and high fasting plasma glucose (FPG) related mortality and DALYs increased among kidney

bladder

and prostate cancers during the study period.

Conclusions:

Kidney

bladder

and prostate cancers remain major global public health challenges

but with distinct trend for different disease entity across different regions and socioeconomic status. More proactive intervention strategies

at both the administrative and academic levels

based on the dynamic changes

are needed.

关键词

Keywords

references

Fitzmaurice C , Abate D , Abbasi N , Abbastabar H , Abd-Allah F , Abdel-Rahman O , et al . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study . JAMA Oncol . 2019 ; 5 ( 12 ): 1749 - 68 .

Zhai Z , Zheng Y , Li N , Deng Y , Zhou L , Tian T , et al . Incidence and disease burden of prostate cancer from 1990 to 2017: results from the Global Burden of Disease Study 2017 . Cancer . 2020 ; 126 ( 9 ): 1969 - 78 .

He H , Xie H , Chen Y , Li C , Han D , Xu F , et al . Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study . BMC Public Health . 2020 ; 20 ( 1 ): 1693 .

Bai X , Yi M , Dong B , Zheng X , Wu K . The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017 . Exp Hematol Oncol . 2020 ; 9 : 27 .

Siegel RL , Miller KD , Jemal A . Cancer statistics, 2019 . CA Cancer J Clin . 2019 ; 69 ( 1 ): 7 - 34 .

Zhang S , Sun K , Zheng R , Zeng H , Wang S , Chen R , et al . Cancer incidence and mortality in China, 2015 . J Natl Cancer Center . 2020 ; 1 ( 1 ): 2 - 11 .

Safiri S , Kolahi AA , Mansournia MA , Almasi-Hashiani A , Ashrafi-Asgarabad A , Sullman MJM , et al . The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990–2017 . Sci Rep . 2020 ; 10 ( 1 ): 13862 .

Richters A , Aben KKH , Kiemeney LALM . The global burden of urinary bladder cancer: an update . World J Urol . 2020 ; 38 ( 8 ): 1895 - 904 .

GBD 2019 Diseases and Injuries Collaborators . Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 . Lancet . 2020 ; 396 ( 10258 ): 1204 - 22 .

GBD 2019 Risk Factors Collaborators . Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 . Lancet . 2020 ; 396 ( 10258 ): 1223 - 49 .

GBD 2019 Demographics Collaborators . Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 . Lancet . 2020 ; 396 ( 10258 ): 1160 - 203 .

Liang G , Fu W , Wang K . Analysis of t-test misuses and SPSS operations in medical research papers . Burns Trauma . 2019 ; 7 : 31 .

Hock LM , Lynch J , Balaji KC . Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data . J Urol . 2002 ; 167 ( 1 ): 57 - 60 .

Fedewa SA , Ward EM , Brawley O , Jemal A . Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States . JAMA Intern Med . 2017 ; 177 ( 7 ): 1040 - 2 .

Goldenberg MG , Skeldon SC , Nayan M , Suppiah Y , Chow L , Fryml E , et al . Prostate-specific antigen testing for prostate cancer screening: a national survey of Canadian primary care physicians’ opinions and practices . Can Urol Assoc J . 2017 ; 11 ( 12 ): 396 - 403 .

Zargar H , van den Bergh R , Moon D , Lawrentschuk N , Costello A , Murphy D . The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia . BJU Int . 2017 ; 119 ( 1 ): 110 - 5 .

Fleshner K , Carlsson SV , Roobol MJ . The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA . Nat Rev Urol . 2017 ; 14 ( 1 ): 26 - 37 .

Ebrahimi H , Amini E , Pishgar F , Moghaddam SS , Nabavizadeh B , Rostamabadi Y , et al . Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD Study 2016 . J Urol . 2019 ; 201 ( 5 ): 893 - 901 .

Teoh JYC , Huang J , Ko WYK , Lok V , Choi P , Ng CF , et al . Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita . Eur Urol . 2020 ; 78 ( 6 ): 893 - 906 .

Culp MB , Soerjomataram I , Efstathiou JA , Bray F , Jemal A . Recent global patterns in prostate cancer incidence and mortality rates . Eur Urol . 2020 ; 77 ( 1 ): 38 - 52 .

Zi H , Peng M , Wang J , Hu H , Yang L , Yao H , et al . An analysis of disease burden of bladder cancer in China from 1990 to 2017 . Yixue Xinzhi Zazhi . 2020 ; 30 ( 5 ): 328 - 35 . (Article in Chinese)

Deng T , Cai L , Chen Z , Guo J , Huang X , Ke C , et al . Analysis of the burden of prostate cancer in China in 1990 and 2017 . Yixue Xinzhi Zazhi . 2020 ; 30 ( 4 ): 252 - 9 . (Article in Chinese)

Cumberbatch MG , Rota M , Catto JW , La Vecchia C . The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks . Eur Urol . 2016 ; 70 ( 3 ): 458 - 66 .

Colt JS , Friesen MC , Stewart PA , Donguk P , Johnson A , Schwenn M , et al . A case–control study of occupational exposure to metalworking fluids and bladder cancer risk among men . Occup Environ Med . 2014 ; 71 ( 10 ): 667 - 74 .

Pesch B , Taeger D , Johnen G , Gawrych K , Bonberg N , Schwentner C , et al . Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines . Int Arch Occup Environ Health . 2014 ; 87 ( 7 ): 715 - 24 .

Capitanio U , Bensalah K , Bex A , Boorjian SA , Bray F , Coleman J , et al . Epidemiology of renal cell carcinoma . Eur Urol . 2019 ; 75 ( 1 ): 74 - 84 .

Tan C , Tang CZ , Chen XS , Luo YJ . Association between medical resources and the proportion of oldest-old in the Chinese population . Mil Med Res . 2021 ; 8 ( 1 ): 14 .

Zakumumpa H , Bennett S , Ssengooba F . Leveraging the lessons learned from financing HIV programs to advance the universal health coverage (UHC) agenda in the East African Community . Glob Health Res Policy . 2019 ; 4 : 27 .

Maluf FC , Gillessen S . Consensus on the screening, staging, treatment, and surveillance of localized, recurrent, and metastatic prostate cancer: the first global prostate cancer consensus conference for developing countries . JCO Glob Oncol . 2021 ; 7 : 512 - 5 .

Rini B , Abel EJ , Albiges L , Bex A , Brugarolas J , Bukowski RM , et al . Summary from the Kidney Cancer Association’s inaugural think thank: coalition for a cure . Clin Genitourin Cancer . 2021 ; 19 ( 2 ): 167 - 75 .

Hamilton AC , Donnelly DW , Loughrey MB , Turkington RC , Fox C , Fitzpatrick D , et al . Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study . Br J Cancer . 2021 ; 21 : 750 .

Viasus D , Cordero E , Rodríguez-Baño J , Oteo JA , Fernández-Navarro A , Ortega L , et al . Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season . Clin Microbiol Infect . 2012 ; 18 ( 3 ): E55 - 62 .

Ángeles-Sistac D , Martin-Onraet A , Cornejo-Juárez P , Volkow P , Pérez-Jimenez C , Vilar-Compte D . Influenza in patients with cancer after 2009 pandemic AH1N1: an 8-year follow-up study in Mexico . Influenza Other Respi Viruses . 2020 ; 14 ( 2 ): 196 - 203 .

Teoh JYC , Ong WLK , Gonzalez-Padilla D , Castellani D , Dubin JM , Esperto F , et al . A global survey on the impact of COVID-19 on urological services . Eur Urol . 2020 ; 78 ( 2 ): 265 - 75 .

Wallis CJD , Catto JWF , Finelli A , Glaser AW , Gore JL , Loeb S , et al . The impact of the COVID-19 pandemic on genitourinary cancer care: re-envisioning the future . Eur Urol . 2020 ; 78 ( 5 ): 731 - 42 .

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021

Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019

Epidemiological trends of subarachnoid hemorrhage at global, regional, and national level: a trend analysis study from 1990 to 2021

Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study

Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046

Related Author

Hao Zi

Meng-Yang Liu

Li-Sha Luo

Peng-Cheng Luo

Hang-Hang Luan

Jiao Huang

Dan-Qi Wang

Yong-Bo Wang

Related Institution

Evidence-Based Medicine Center, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine

Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University

Department of Urology, Wuhan Third Hospital, Tongren Hospital of Wuhan University

Department of Forensic Medicine, Zhongnan Hospital of Wuhan University

School of Clinical Medicine, Hubei University of Arts and Science

⁰